News
ELOX
10.69
+0.38%
0.04
Eloxx Pharmaceuticals’ exaluren shows efficacy in Alport syndrome trial
TipRanks · 2d ago
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
PR Newswire · 2d ago
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Henry Schein (HSIC) and Eloxx Pharmaceuticals (ELOX)
TipRanks · 3d ago
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
NASDAQ · 4d ago
Eloxx Pharmaceuticals GAAP EPS of -$0.49 beats by $0.09
Seeking Alpha · 4d ago
*Eloxx Pharmaceuticals: As of Sept 30, Had Cash and Cash Equivalents of $56.3M >ELOX
Dow Jones · 4d ago
*Eloxx Pharmaceuticals 3Q Loss/Shr 49c >ELOX
Dow Jones · 4d ago
*Eloxx Pharmaceuticals 3Q Loss $5.54M >ELOX
Dow Jones · 4d ago
Press Release: Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 4d ago
Press Release: Eloxx Pharmaceuticals Reports -2-
Dow Jones · 4d ago
Eloxx Pharma Q3 EPS $(0.49) Beats $(0.58) Estimate
Benzinga · 4d ago
Weekly Report: what happened at ELOX last week (1109-1113)?
Weekly Report · 4d ago
Weekly Report: what happened at ELOX last week (1102-1106)?
Weekly Report · 11/09 10:11
Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
PR Newswire · 11/02 21:15
Weekly Report: what happened at ELOX last week (1026-1030)?
Weekly Report · 11/02 10:11
Eloxx Pharmaceuticals announces FDA clearance of IND application for exaluren
TipRanks · 10/29 12:05
Eloxx Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones · 10/28 13:57
Eloxx Pharmaceuticals Price Target Cut to $40.00/Share From $43.00 by Guggenheim
Dow Jones · 10/28 13:57
Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40
Benzinga · 10/28 13:47
Eloxx Pharmaceuticals price target lowered to $40 from $43 at Guggenheim
TipRanks · 10/28 11:20
More
Webull provides a variety of real-time ELOX stock news. You can receive the latest news about Eloxx Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About ELOX
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.